# Contents

**Chapter 1:** Introduction, aims and outline  

**Chapter 2:** Role of BRI2 in dementia  

**Chapter 3:** BRI2-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer’s disease.  

**Chapter 4:** Accumulation of BRI2-BRICHOS ectodomain correlates with a decreased clearance of Ab by insulin degrading enzyme (IDE) in Alzheimer’s disease.  
*Neurosci Lett.* 2015; 589:47-51  

**Chapter 5:** BRI2 ectodomain affects Aβ_{42} fibrillation and tau truncation in human neuroblastoma cells.  
*Cell Mol Life Sci.* 2015;72(8):1599-611  

**Chapter 6:** SPPL2b is drastically increased in early stages of Alzheimer’s disease and associated with tau pathology.  
*Under review*  

**Chapter 7:** Recommendations to standardize Pre-analytical confounding factors in Alzheimer’s and Parkinson’s disease CSF biomarkers: an update.  

**Chapter 8:** BRI2 correlates with markers reflecting Alzheimer’s disease pathology in human cerebrospinal fluid.  
*In preparation*  

**Chapter 9:** Can agrin CSF concentration be used as an early biomarker for Alzheimer’s disease?  
*Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring;* 2015; 1: 75-80  

**Chapter 10:** General discussion and perspectives  

**Appendix:**  
Nederlandse samenvatting  
List of abbreviations  
List of theses Alzheimer Center  
List of publications  
Curriculum Vitae  
Acknowledgements